𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab

✍ Scribed by Jorge A. Garcia; Thomas E. Hutson; Paul Elson; C. Lance Cowey; Timothy Gilligan; Cheryl Nemec; Robert Dreicer; Ronald M. Bukowski; Brian I. Rini

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
249 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prognostic nomogram for sunitinib in pat
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi

Cytoreductive nephron-sparing surgery do
Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
✍ Georg C. Hutterer; Jean-Jacques Patard; Marc Colombel; Arie S. Belldegrun; Chris πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The role of nephron‐sparing surgery (NSS) showed promise in patients with metastatic renal cell carcinoma (MRCC). The disease‐specific survival of patients with MRCC was compared according to the type of surgery, NSS (N = 45) versus radical nephrectomy (RN) (N = 732), in